Loading organizations...
§ Private Profile · Bordeaux, Aquitaine, France
Biotechnology company developing a bioproduction platform for cost-effective, scalable mRNA and long non-coding RNA for gene therapies.
Based in Évry, France, south of Paris, bYoRNA develops a bioproduction platform that utilizes recombinant yeast and eukaryotic cells to manufacture messenger RNA and long non-coding RNA at scale. The company's technology serves as an alternative to traditional in vitro transcription methods, enabling the production of longer self-amplifying RNAs while reducing manufacturing costs by up to 100 times to under €1 million per kilogram. Operating a hybrid business model, the firm produces preclinical batches internally and outsources commercial manufacturing to contract organizations in exchange for an eight percent royalty on approved therapeutic drugs. Backed by €1.5 million in funding, the enterprise has secured a development agreement with a NASDAQ-listed bioproduction company and received institutional support from Antler Capital, Génopole, and researcher Chantal Pichon. bYoRNA was founded in 2022 by Pascal Viguié and Thierry Ziegler.
bYoRNA has raised $1.8M across 1 funding round.
bYoRNA has raised $1.8M in total across 1 funding round.
bYoRNA has raised $1.8M across 1 funding round. Most recently, it raised $1.8M Pre-Seed in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 14, 2025 | $1.8M Pre Seed | — | Irdi Capital Investissement, Cécile Tharaud | Announced |
bYoRNA has raised $1.8M in total across 1 funding round.
bYoRNA's investors include IRDI Capital Investissement, Cécile Tharaud.